# Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

> **NCT04946318** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 136 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CSJ117
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04946318
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-08
- **Primary completion:** 2022-09-08
- **Final completion:** 2022-09-08
- **Target enrollment:** 136 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2022-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04946318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04946318, "Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04946318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*